

Molina Healthcare Reports Third Quarter 2022 Financial Results

October 26, 2022

Increases Full-Year 2022 Revenue and Earnings Guidance

LONG BEACH, Calif.--(BUSINESS WIRE)--Oct. 26, 2022-- Molina Healthcare, Inc. (NYSE: MOH) (the "Company") today reported third quarter 2022 GAAP earnings per diluted share of \$3.95 and adjusted earnings per diluted share of \$4.36. Financial results are summarized below:

	Quarter	ended	Nine mon	ths ended
	Septem	ber 30,	Septem	nber 30,
	2022	2021	2022	2021
(le re'll'erre except and bear months)				
(In millions, except per-share results)				
Premium Revenue	\$7,636	\$6,800	\$22,966	\$19,689
Total Revenue	\$7,927	\$7,040	\$23,751	\$20,362
GAAP:				
Net Income	\$230	\$143	\$736	\$556
EPS – Diluted	\$3.95	\$2.46	\$12.58	\$9.51
Medical Care Ratio (MCR)	88.4%	88.9%	87.9%	88.1%
G&A Ratio	7.1%	7.5%	7.1%	7.3%
After-tax Margin	2.9%	2.0%	3.1%	2.7%
Adjusted:				
Net Income	\$254	\$164	\$808	\$623
EPS – Diluted	\$4.36	\$2.83	\$13.81	\$10.66
G&A Ratio	6.9%	7.3%	6.9%	7.1%
After-tax Margin	3.2%	2.3%	3.4%	3.1%
See the Reconciliation of Unaudited Non-GAAP Financial	Measures at the en	d of this release		

Quarter Highlights

- As of September 30, 2022, the Company served approximately 5.2 million members, an increase of 337,000 members or 7% compared to September 30, 2021.
- Premium revenue was approximately \$7.6 billion for the third quarter of 2022, an increase of 12% compared to the third quarter of 2021.
- Third quarter of 2022 GAAP earnings per diluted share were \$3.95 and adjusted earnings per diluted share were \$4.36, an increase of 61% and 54% respectively compared to the third quarter of 2021.
- The Company increased its full year 2022 premium revenue guidance to approximately \$30.5 billion, above its previous guidance of approximately \$30 billion.
- The Company increased its full year 2022 adjusted earnings guidance to at least \$17.75 per diluted share, above its previous guidance of at least \$17.60 per diluted share.

"We are very pleased with our third quarter financial and operating performance, which includes the announcement of significant new business wins," said Joseph Zubretsky, President and Chief Executive Officer. "We executed well, delivered strong operating earnings, and continued to deliver on our growth strategy. Our projected 2022 earnings baseline is solid, and the embedded earnings power of the company continues to build. In summary, the company's financial and operational performance validates our long-term revenue growth strategy and its value creation potential."

Premium Revenue

Premium revenue was approximately \$7.6 billion for the third quarter of 2022, an increase of 12% compared to the third quarter of 2021. The higher premium revenue reflects the impact of acquisitions and increased organic membership in the Medicaid and Medicare lines of business.

Net Income

GAAP net income for the third quarter of 2022 was \$3.95 per diluted share, compared to \$2.46 per diluted share in the third quarter of 2021. Adjusted net income for the third quarter of 2022 was \$4.36 per diluted share, compared to \$2.83 per diluted share in the third quarter of 2021. The net effect of COVID decreased the third quarter of 2022 GAAP and adjusted EPS by \$0.59 per diluted share, compared to a decrease of \$1.00 per diluted share in

the third quarter of 2021.

Medical Care Ratio

- The consolidated MCR for the third quarter of 2022 was 88.4%, compared to 88.9% for third quarter of 2021. The net effect of COVID added approximately 60 basis points to the consolidated MCR in the third quarter of 2022, compared to 110 basis points added to the MCR in the third quarter of 2021. The impact varied by segment. On a year-to-date basis the consolidated MCR was 87.9%.
- The Medicaid MCR for the third quarter was 88.5%. The net effect of COVID added approximately 10 basis points in the quarter. On a year-to-date basis the Medicaid MCR was 88.2%, at the lower end of the Company's long-term target range.
- The Medicare MCR for the third quarter was 88.7%. The net effect of COVID added approximately 350 basis points in the quarter. On a year-to-date basis the Medicare MCR was 87.4%, in line with the Company's long-term target range.
- The Marketplace MCR for the third quarter was 86.3%. The net effect of COVID added approximately 90 basis points in the quarter. On a year-to-date basis the Marketplace MCR was 85.1%.

General and Administrative Expense Ratio

The G&A ratio for the third quarter of 2022 was 7.1%, compared to 7.5% for the third quarter of 2021. The adjusted G&A ratio was 6.9% for the third quarter of 2022, compared to 7.3% for the third quarter of 2021. The year over year improvement reflects disciplined cost management and the benefits of fixed cost leverage produced by our increase in revenue.

Balance Sheet

Cash and investments at the parent company were \$298 million as of September 30, 2022, compared to \$348 million as of December 31, 2021.

Cash Flow

Operating cash flow for the nine months ended September 30, 2022, was \$985 million, which was lower compared to the nine months ended September 30, 2021, primarily due to the net impact of timing differences in government receivables and payables partially offset by the impact of increased net earnings.

2022 Guidance

Premium revenue for full year 2022 is now expected to be approximately \$30.5 billion, above the previous guidance of approximately \$30 billion. The increase of \$500 million includes third quarter outperformance, the addition of the AgeWell acquisition, which closed October 1, 2022, and the expected impact of the extension of the Public Health Emergency from October to January 2023.

The Company increased its full year 2022 adjusted earnings guidance to at least \$17.75 per diluted share, above the previous guidance of at least \$17.60 per diluted share. The increase above previous guidance is driven by third quarter outperformance, expected margin on additional revenue resulting from the extension of the Public Health Emergency and higher expected net investment income, partially offset by higher expected G&A driven by fourth quarter marketing and open enrollment activities and new contract wins.

See the Reconciliation of Unaudited Non-GAAP Financial Measures at the end of this release.

Conference Call

Management is hosting a conference call and webcast to discuss Molina Healthcare's third quarter 2022 results at 8:00 a.m. Eastern Time on Thursday, October 27, 2022. The number to call for the interactive teleconference is (877) 883-0383 and the confirmation number is 7246369. A telephonic replay of the conference call will be available through Thursday, November 10, 2022, by dialing (877) 344-7529 and entering confirmation number 8349243. A live audio broadcast of this conference call will be available on Molina Healthcare's website, molinahealthcare.com. A 30-day online replay will be available approximately an hour following the conclusion of the live broadcast.

About Molina Healthcare

Molina Healthcare, Inc., a FORTUNE 500 company (currently ranked 125), provides managed healthcare services under the Medicaid and Medicare programs and through the state insurance marketplaces. Molina Healthcare served approximately 5.2 million members as of September 30, 2022, located across 19 states. For more information about Molina Healthcare, please visit molinahealthcare.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This earnings release and the Company's accompanying oral remarks contain forward-looking statements regarding its 2022 guidance, as well as its plans and expectations regarding future developments. Actual results could differ materially due to numerous known and unknown risks and uncertainties. These risks and uncertainties are discussed under the headings "Forward-Looking Statements," and "Risk Factors," in the Company's Annual Report on Form 10-K for the year ended December 31, 2021, which is on file with the SEC, and also in its Quarterly Report on Form 10-Q for the three months ended September 30, 2022, which the Company expects to file on or about October 27, 2022.

These reports can be accessed under the investor relations tab of the Company's website or on the SEC's website at sec.gov. Given these risks and uncertainties, the Company can give no assurances that its forward-looking statements will prove to be accurate, or that any other results or developments projected or contemplated by its forward-looking statements will in fact occur, and the Company cautions investors not to place undue reliance on these statements. All forward-looking statements in this release represent the Company's judgment as of October 26, 2022, and, except as otherwise required by law, the Company disclaims any obligation to update any forward-looking statement to conform the statement to actual results or

MOLINA HEALTHCARE, INC. UNAUDITED CONSOLIDATED STATEMENTS OF INCOME

		Three Mor			Nine Months Ended September 30,			
		2022		2021		2022		2021
		(In I	millio	ıs, except	per-	share amou	ınts)	
Revenue:	_							
Premium revenue	\$	7,636	\$	6,800	\$	22,966	\$	19,689
Premium tax revenue		223		204		646		576
Investment income		49		20		82		39
Other revenue		19		16		57		58
Total revenue		7,927		7,040		23,751		20,362
Operating expenses:								
Medical care costs		6,748		6,049		20,183		17,342
General and administrative expenses		560		532		1,682		1,489
Premium tax expenses		223		204		646		576
Depreciation and amortization		45		32		129		96
Other		16_		2		43		30
Total operating expenses		7,592		6,819		22,683		19,533
Operating income		335		221		1,068		829
Other expenses, net:								
Interest expense		28		30		83		90
Total other expenses, net		28		30		83		90
Income before income tax expense		307		191		985		739
Income tax expense		77		48		249		183
•	\$	230	\$	143	\$	736	\$	556
Net income	Φ	230	Ф	143	Ф	730	Þ	556
Net income per share – Diluted	\$	3.95	\$	2.46	\$	12.58	\$	9.51
Diluted weighted average shares outstanding	_	58.3		58.5		58.5		58.5
Operating Statistics:								
Medical care ratio		88.4%		88.9%		87.9%		88.1%
G&A ratio		7.1%		7.5%		7.1%		7.3%
Premium tax ratio		2.8%		2.9%		2.7%		2.8%
Effective income tax rate		24.9%		24.8%		25.2%		24.7%
After-tax margin		2.9%		2.0%		3.1%		2.7%
	LINA HEALTHCARE, IN LIDATED BALANCE SI							
				-	tember 30, De 2022			nber 31, 021
				Unau				,

		_	2021				
	Unaudited						
	(Dollar	s in millio	ns,				
	except per	\$ 4,242 \$ 3,639 2,220 391 10,492 412 1,263 242 198	except per-share amounts)				
ASSETS							
Current assets:							
Cash and cash equivalents	\$ 4,242	\$	4,438				
Investments	3,639		3,202				
Receivables	2,220		2,177				
Prepaid expenses and other current assets	391		247				
Total current assets	10,492		10,064				
Property, equipment, and capitalized software, net	412		396				
Goodwill and intangible assets, net	1,263		1,252				
Restricted investments	242		212				
Deferred income taxes	198		106				
Other assets	186		179				

Total assets	\$	12,793	\$ 12,209
LIABILITIES AND STOCKHOLDERS' EQUITY			
Current liabilities:			
Medical claims and benefits payable	\$	3,622	\$ 3,363
Amounts due government agencies		2,139	2,472
Accounts payable, accrued liabilities and other		818	842
Deferred revenue		663	 370
Total current liabilities		7,242	 7,047
Long-term debt		2,175	2,173
Finance lease liabilities		217	219
Other long-term liabilities		118	 140
Total liabilities		9,752	 9,579
Stockholders' equity:			
Common stock, \$0.001 par value, 150 million shares authorized; outstanding: 58 million shares at			
September 30, 2022 and December 31, 2021		_	_
Preferred stock, \$0.001 par value; 20 million shares authorized, no shares issued and outstanding		_	_
Additional paid-in capital		289	236
Accumulated other comprehensive loss		(185)	(5)
Retained earnings		2,937	 2,399
Total stockholders' equity		3,041	2,630
Accounts payable, accrued liabilities and other Deferred revenue Total current liabilities ong-term debt inance lease liabilities other long-term liabilities otal liabilities tockholders' equity: Common stock, \$0.001 par value, 150 million shares authorized; outstanding: 58 million shares at September 30, 2022 and December 31, 2021 Preferred stock, \$0.001 par value; 20 million shares authorized, no shares issued and outstanding Additional paid-in capital Accumulated other comprehensive loss Retained earnings		12,793	\$ 12,209

MOLINA HEALTHCARE, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Nine Months Ended September 30,

\$ 736 129 (35) 80	2021 nillions) \$ 556 96 (8) 49
\$ 736 129 (35) 80	\$ 556 96 (8)
\$ 736 129 (35) 80	\$ 556 96 (8)
129 (35) 80	96 (8)
(35) 80	(8)
(35) 80	(8)
80	
	40
(3)	73
(-)	9
(15)	(247)
(110)	(43)
251	522
(360)	810
(40)	129
293	(374)
59	23
985	1,522
(1,764)	(2,018)
1,082	965
(134)	_
(81)	(56)
(41)	3
(938)	(1,106)
(200)	(128)
(53)	(52)
(20)	(20)
15	(4)
(258)	(204)
	212
	(3) (15) (110) 251 (360) (40) 293 59 985 (1,764) 1,082 (134) (81) (41) (938) (200) (53) (20)

Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period Cash, cash equivalents, and restricted cash and cash equivalents at end of period

 4,506	4,223
\$ 4,295	\$ 4,435

MOLINA HEALTHCARE, INC. UNAUDITED SEGMENT DATA (Dollars in millions)

	September 30,	December 31,	September 30,
	2022	2021	2021
Ending Membership by Segment:			
Medicaid	4,667,000	4,329,000	3,981,000
Medicare	155,000	142,000	138,000
Marketplace	353,000	728,000	719,000
Total	5,175,000	5,199,000	4,838,000

Three Months Ended September 30,

			2022		2021						
	Premium Revenue			MCR ⁽¹⁾		Premium Revenue		Medical Margin	MCR ⁽¹⁾		
Medicaid	\$ \$ 6,125		703	88.5%	\$	5,146		532	89.6%		
Medicare	947		108	88.7		875		151	82.8		
Marketplace	 564		77	86.3		779		68	91.3		
Consolidated	\$ 7,636	\$	888	88.4%	\$	6,800	\$	751	88.9%		

Nine Months Ended September 30.

			2022			2021								
	Premium Revenue			MCR ⁽¹⁾		Premium Revenue		Medical Margin	MCR ⁽¹⁾					
Medicaid	\$ 18,406	\$	2,168	88.2%	\$	15,020	\$	1,687	88.8%					
Medicare	2,847		360	87.4		2,488		329	86.8					
Marketplace	 1,713		255	85.1		2,181		331	84.8					
Consolidated	\$ 22,966	\$	2,783	87.9%	\$	19,689	\$	2,347	88.1%					

⁽¹⁾ The MCR represents medical costs as a percentage of premium revenue.

MOLINA HEALTHCARE, INC. CHANGE IN MEDICAL CLAIMS AND BENEFITS PAYABLE (Dollars in millions)

The Company's claims liabilities include additional reserves to account for moderately adverse conditions based on historical experience and other factors including, but not limited to, variations in claims payment patterns, changes in utilization and cost trends, known outbreaks of disease, and large claims. The Company's reserving methodology is consistently applied across all periods presented. The amounts displayed for "Components of medical care costs related to: Prior year" represent the amounts by which the original estimates of claims and benefits payable at the beginning of the year were more than the actual liabilities based on information (principally the payment of claims) developed since those liabilities were first reported. The following table presents the components of the change in medical claims and benefits payable for the periods indicated:

Nine Months Ended September 30.

	epicinisci co,							
		2021						
		Una	udited					
Medical claims and benefits payable, beginning balance	\$	3,363	\$	2,696				
Components of medical care costs related to:								
Current year		20,521		17,558				
Prior year		(338)		(216)				
Total medical care costs		20,183		17,342				
Payments for medical care costs related to:								
Current year		17,538		14,880				
Prior year		2,481		2,008				
Total paid		20,019		16,888				
Acquired balances, net of post-acquisition adjustments		8		(27)				

Change in non-risk and other provider payables	87	68
Medical claims and benefits payable, ending balance	\$ 3,622	\$ 3,191
Days in Claims Payable ⁽¹⁾	50	49

⁽¹⁾ The Company calculates Days in Claims Payable using claims incurred but not paid, or IBNP, and other fee-for-service payables included in medical claims and benefits payable, and quarterly fee-for-service related costs included in medical care costs within the Company's consolidated financial statements.

MOLINA HEALTHCARE, INC. RECONCILIATION OF UNAUDITED NON-GAAP FINANCIAL MEASURES (In millions, except per diluted share amounts)

The Company believes that certain non-GAAP (generally accepted accounting principles) financial measures are useful supplemental measures to investors in comparing the Company's performance to the performance of other public companies in the health care industry. The non-GAAP financial measures are also used internally to enable management to assess the Company's performance consistently over time. These non-GAAP financial measures, presented below, should be considered as supplements to, and not as substitutes for or superior to, GAAP measures.

Adjustments represent additions and deductions to GAAP net income as indicated in the table below, which include the non-cash impact of amortization of acquired intangible assets, acquisition-related expenses, and the impact of certain expenses and other items that management believes are not indicative of longer-term business trends and operations.

Adjusted G&A Ratio represents the GAAP G&A ratio, recognizing adjustments.

Adjusted net income represents GAAP net income recognizing the adjustments, net of tax. The Company believes that adjusted net income is helpful to investors in assessing the Company's financial performance.

Adjusted net income per diluted share represents adjusted net income divided by weighted average common shares outstanding on a fully diluted basis.

Adjusted after-tax margin represents adjusted net income, divided by total revenue.

		Thre	e M	onths En	ded	Septemb	er 3	0,	Nine Months Ended September 30,								
		2	022		2021					2		2021					
	Α	mount		Per Diluted Share	Α	mount		Per Diluted Share	Α	mount		Per Diluted Share	Α	mount		Per Diluted Share	
Net income	\$	230	\$	3.95	\$_	143	\$	2.46	<u>\$</u>	736	<u>\$</u>	12.58	\$	556	\$	9.51	
Adjustments:																	
Amortization of intangible assets		19		0.33		11		0.20		56		0.96		35		0.60	
Acquisition-related expenses (1)		12		0.21		17		0.28		38		0.65		44		0.75	
Other (2)		_		_		_		_		_		_		9		0.16	
Subtotal, adjustments		31		0.54		28		0.48		94		1.61		88		1.51	
Income tax effect		(7)		(0.13)		(7)		(0.11)		(22)		(0.38)		(21)		(0.36)	
Adjustments, net of tax		24		0.41		21		0.37		72		1.23		67		1.15	
Adjusted net income	\$	254	\$	4.36	\$	164	\$	2.83	\$	808	\$	13.81	\$	623	\$	10.66	

⁽¹⁾ Reflects non-recurring costs associated with acquisitions, including various transaction and integration costs.

MOLINA HEALTHCARE, INC. RECONCILIATION OF UNAUDITED NON-GAAP FINANCIAL MEASURES (CONTINUED) 2022 GUIDANCE

		Amount		Diluted Share ⁽²⁾	
Net income	\$	944	\$	16.13	
Adjustments:					
Amortization of intangible assets		77		1.31	
Acquisition-related expenses		47		0.82	
Subtotal, adjustments		124		2.13	
Income tax effect (1)		(30)		(0.51)	

⁽²⁾ The nine months ended September 30, 2022 includes certain non-recurring costs associated with gain on lease termination and disposal of fixed assets. The nine months ended September 30, 2021 includes change in premium deficiency reserves, loss on sale of property, and restructuring costs.

Adjustments, net of tax	 94	1.62
Adjusted net income per diluted share	\$ 1,038	\$ 17.75

⁽¹⁾ Income tax effect calculated at the statutory tax rate of approximately 23.9%.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221026005765/en/

Investor Contact: Joseph Krocheski, <u>Joseph.Krocheski@molinahealthcare.com</u>, 562-951-8382 Media Contact: Caroline Zubieta, <u>Caroline.Zubieta@molinahealthcare.com</u>, 562-951-1588

Source: Molina Healthcare, Inc.

⁽²⁾ Computations assume approximately 58.5 million diluted weighted average shares outstanding.